Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
This grant supports small businesses in advancing their drug discovery projects for nervous system disorders, providing funding and collaboration opportunities with NIH consultants and research organizations. Projects can enter at either the discovery or development stage, with the potential to continue through to phase I clinical testing. Awardees retain intellectual property rights for developed drug candidates.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: November 17, 2025 (final application deadline)
Funding Amounts: Award amount not specified; funding supports multi-stage small molecule drug discovery and development projects by small businesses.
Summary: Supports small businesses in advancing small molecule drug discovery and development for nervous system disorders, with access to NIH resources and expertise.
Key Information: Eligible only to U.S. small businesses; foreign entities cannot apply.
Description
This opportunity supports small businesses engaged in the discovery and development of small molecule therapeutics targeting disorders of the nervous system. The program offers a collaborative environment through the Blueprint Neurotherapeutics Network (BPN), providing funding, access to NIH-funded consultants, and specialized contract research organizations (CROs) for medicinal chemistry, pharmacokinetics, toxicology, formulations, GMP synthesis, and Phase I clinical testing. Projects may enter at either the Discovery or Development stage, with the potential to progress through IND-enabling studies and early clinical trials. Awardee institutions retain intellectual property rights for drug candidates developed under this program.
